Darwin Wealth Management’s Axsome Therapeutics AXSM Stock Holding History

Darwin Wealth Management’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$184	Buy	+1	New	+$218	﹤0.01%	1106

Other funds holding AXSM

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return

Darwin Wealth Management's AXSM Position: Q3 2026 in Review

Darwin Wealth Management opened a new position in Axsome Therapeutics (AXSM) in Q3 2026: 1 share worth $184. The stake represents ﹤0.01% of the portfolio and ranks #1106 among its holdings.

235 funds tracked by Wall St. Rank hold AXSM as of Q3 2026.

Darwin Wealth Management held 1 share of Axsome Therapeutics worth $184 as of Q3 2026.
Axsome Therapeutics was a new Darwin Wealth Management position in Q3 2026.
Axsome Therapeutics made up ﹤0.01% of Darwin Wealth Management's portfolio in Q3 2026, its #1106 holding.
235 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2026.

Based on Darwin Wealth Management's 13F filing for Q3 2026, filed 9 Nov 2026.